MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/gutjnl-2025-335998

Медицинская библиотека · Gut · 2025

Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure.

Xu Xianbin, Chen Jiyang, Yu Xia, Li Zhiwei, Chen Jianing, Fang Danfeng, Lin Xingchen, Tu Huilan, Xu Xinyi, Yang Sisi, Cheng Jinlin, Gong Kai, Weng Haoda, Yu Yue, Zhang Xiuding, Lan Yan, Li Biao, Cao Guoqiang, Chen Hai, Chen Leiming, Qian Xiaohan, Han Wenzheng, Jiang Meng, Du Weibo, Yang Yida, Sheng Jifang, Wu Xiaopeng, Shi Yu

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Acute-on-chronic liver failure (ACLF) is characterised by intense systemic inflammation and high short-term mortality, yet effective targeted therapies are lacking.

OBJECTIVE

To explore monocyte heterogeneity in HBV-related ACLF (HBV-ACLF) to identify specific subsets and associated therapeutic targets.

DESIGN

Peripheral blood mononuclear cells from healthy controls (n=4), patients with acute decompensation (n=5), and patients with ACLF (n=9) underwent single-cell RNA sequencing (scRNA-seq). Findings were integrated with hepatic scRNA-seq, bulk transcriptomics, multiplex immunohistochemistry and in vitro functional assays. The in vivo roles of candidate targets were validated in two murine ACLF models.

RESULTS

We identified a distinct RETN+ monocyte subset that was expanded in the circulation and liver of patients with HBV-ACLF. These RETN+ monocytes displayed a transcriptional programme enriched for anti-inflammatory and pro-resolving signatures, including MS1-B-like features. Interleukin-6 promoted the expansion of RETN+ monocyte via the JAK/STAT3/RUNX1 signalling axis. In murine ACLF models, neutralisation of Resistin exacerbated liver injury, increased systemic cytokine levels and augmented hepatocyte apoptosis. Conversely, administration of recombinant Resistin mitigated liver damage, diminished levels of inflammatory cytokines and improved survival. Mechanistically, Resistin activated PI3K/AKT signalling in hepatocytes, preserved the Bcl-2/Bax balance and suppressed intrinsic apoptosis. Clinically, plasma Resistin levels in HBV-ACLF patients inversely correlated with systemic inflammatory markers, liver injury, ACLF severity scores (Model for End-Stage Liver Disease, Chronic Liver Failure Consortium ACLF score) and short-term mortality.

CONCLUSIONS

RETN+ monocytes constitute a distinct immunoregulatory subset enriched in HBV-ACLF, and their product, Resistin, exerts significant hepatoprotective and anti-inflammatory effects. These findings highlight RETN+ monocytes and Resistin as promising immunotherapeutic targets for HBV-ACLF.

Для цитирования: Xu Xianbin, Chen Jiyang, Yu Xia, Li Zhiwei, Chen Jianing, Fang Danfeng, Lin Xingchen, Tu Huilan, Xu Xinyi, Yang Sisi, Cheng Jinlin, Gong Kai, Weng Haoda, Yu Yue, Zhang Xiuding, Lan Yan, Li Biao, Cao Guoqiang, Chen Hai, Chen Leiming, Qian Xiaohan, Han Wenzheng, Jiang Meng, Du Weibo, Yang Yida, Sheng Jifang, Wu Xiaopeng, Shi Yu. Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure.. Gut. 2025. DOI: 10.1136/gutjnl-2025-335998.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.